Title A novel dual DYRK1A/B inhibitor for the treatment of type 1 diabetes
Authors Tumas, Šarūnas ; Mingaila, Jonas ; Baranauskas, Vytautas ; Baltrukonytė, Emilija ; Orla, Laurynas ; Krasko, Jan Aleksander ; Pocevičiūtė, Roberta ; Berlina, Dina ; Belenky, Alexei ; Vilenchik, Maria ; Vaitkevičienė, Agnė ; Potapova, Olga ; Burokas, Aurelijus
DOI 10.3389/fphar.2025.1657042
Full Text Download
Is Part of Frontiers in pharmacology.. Lausanne : Frontiers Media SA. 2025, vol. 16, art. no. 1657042, p. [1-9].. eISSN 1663-9812
Keywords [eng] DYRK1 ; DYRK1A kinase ; DYRK1B kinase ; GTT ; streptozotocin ; type 1 diabetes
Abstract [eng] Background: Type 1 diabetes (T1D) is an autoimmune disease that leads to the progressive destruction of pancreatic β cells, resulting in insulin deficiency and hyperglycemia. Current treatments focus on insulin replacement, but novel therapeutic approaches targeting β cell regeneration are needed. Dual-specificity tyrosine-phosphorylation-regulated kinases 1A (DYRK1A) and 1B (DYRK1B) play key roles in cell cycle regulation and β cell proliferation. Methods: In this study, FX8474, a novel DYRK1 inhibitor, was evaluated in a streptozotocin (STZ)-induced diabetic mouse model. Mice were treated orally for 7 days, and pharmacokinetics, glucose regulation, and immune cell profiling were assessed. Results: Pharmacokinetic analysis confirmed the oral bioavailability of FX8474, and treatment was associated with improved fasted glucose levels and glucose tolerance after a 7-day treatment. Immunophenotyping indicated that FX8474 treatment increases CD4+ memory T cell populations while decreasing CD4+ effector cells, as well as restores CD8+ T cell phenotypes to levels observed in healthy mice. Conclusion: FX8474 has a modest effect on glucose regulation and immune cell composition, warranting further investigation into its potential therapeutic applications.
Published Lausanne : Frontiers Media SA
Type Journal article
Language English
Publication date 2025
CC license CC license description